AGE, Advanced Glycation End Products: HRPOCatalogue number: AGE612HRP
This antibody is suitable for the detection of different AGE products in tissues, tissue extracts and body fluids. Long-term incubation of proteins with glucose leads, through Schiff's base and Amadori rearrangement products, to the formation of advanced glycation end products (AGE) which are characterized by fluorescence, brown color and inter- and intra-molecular cross-linking. Recent immunological studies using anti-AGE antibodies demonstrated the presence of AGE in (i) human lens, (ii) renal proximal tubules in patients with diabetic nephropathy and chronic renal failure, (iii) atherosclerotic lesions of arterial walls, (iv) ß2-microglobulin of carpal tunnel amyloid fibril deposits in patients with hemodialysis-related amyloidosis and (v) brain tissues of patients with Alzheimer’s disease. These results suggested the potential role of AGE in normal aging and age-enhanced disease processes. Positive: Advanced Glycation Endproducts, AGE-HSA, AGE-BSA, AGE-Hb, AGE-Collagen,AGE-Lys-derivatives (AGE-alpha-Tos-Lys, AGE-alpha-Tos-Lys-o-Me), AGE-monoamino carboxylic acids (AGE-beta-Alanine, AGE-gamma-aminobutyric acid, AGE-epsilon-aminocaproic acid) - negativ: early stages of the Maillard reaction (Schiff's base adducts, Amadori rearrangement products), unmodified protein HSA, BSA, Hb, Collagen, poly-Lys, Lys-derivatives (alpha-Tos-Lys, alpha-Tos-Lys-o-Me), unmodified monoamino carboxylic acids (beta-alanine, gamma-amino butyric acid, epsilon-aminocaproic acid), FFI, Pyrrole aldehyde, Pentosidine..
Immunogen: Advanced Glycation End Products-BSA
Protein G affinity purified antibody from ascites in stabilized buffer, containing 50% Block Ace? (Casein-containing solution, Dainippon Co.) and 0.1% ProClin? (Rohm & Haas) as a preservative
Purification Method: Protein G affinity purified antibody from ascites in stabilized buffer, containing 50% Block Ace? (Casein-containing solution, Dainippon Co.) and 0.1% ProClin? (Rohm & Haas) as a preservative
Concentration: 0.1 mg/ml
Secondary Reagents: Peroxidase substrate like AEC (Art. No. AE002) and DAB (Art. No. DA002) for IHC or OPD, TMB and ABTS for ELISA.
Species Reactivity: Human
Incubation Time: 60 min at RT or 18 hr at 2-8°C
Working Concentration: (liquid conc.) ELISA 0.1-0.5 µg/ml; IHC 2 µg/ml
Positive Control: human lens, arteriosclerotic plaques
These antibodies are intended for in vitro research use only. They must not be used for clinical diagnostics and not for in vivo experiments in humans or animals.
1. Horiuchi S., Araki N., and Morino Y. (1991) Immunological approach to characterize advanced glycation end products of the Maillard reaction: Evidence for the presence of a common stucture. J. Biol. Chem. 266; 7329-7332. 2. Akari N., Ueno N., Chakrabarti B., Morino Y., and Horiuchi S. (1992) Immunochemical evidence of the presence of advanced glycation end products in human lens proteins and its positive correlation with aging. J. Biol. Chem. 267; 10211-10214. 3. Miyata T., Odo O., Inagi R., Iida Y., Araki N., Yamada N., Horiuchi S., Taniguchi N., Maeda, et al. (1993) ß2-Microglobulin modified with advanced glycation end products is a major component of haemodialysis-associated amyloidosis. J. Clin. Invest. 92; 1243-1252. 4. Kume S., Takeya M., Mori T., Araki N., Suzuki H., Horiuchi S., Kodama T., Miyauchi Y., and Takahashi K. (1995) Immunohistochemical and ultrastructural detection of advanced glycation end products in atherosclerotic lesions of human aorta using a novel specific monoclonal antibody. Am J. Pathol. 147; 654-667. 5. Kimura T., Takamatsu J., Ikeda K., Kondo A., Miyakawa T., and Horiuchi S. (1996) Accumulation of advanced glycation end products of the Maillard reaction with age in human hippocampal neurons. Neurosci. Lett. 208; 53-56.
AGE, Advanced Glycation End Products: HRPO